Mendil100 ml

Mendil is a topical combination product used for the short-term, symptomatic relief of itching (pruritus) and minor skin irritation. Established, labelled uses include:

• Itching due to insect bites and stings — an established topical antipruritic use.
• Minor skin irritation, rashes, and allergic skin reactions (e.g. contact with mild irritants, minor hives) — established use for temporary itch relief.
• Minor sunburn and superficial skin abrasions — commonly used for symptomatic relief of associated itching and discomfort, based on OTC monograph-level evidence rather than formal clinical trial data.

Mendil does not treat the underlying cause of a rash or skin condition; it only relieves the symptom of itching. It is not intended for systemic allergic reactions, anaphylaxis, or widespread or infected skin disease, which require alternative medical management.

Each application of Diphenhydramine + Levomenthol contains diphenhydramine hydrochloride, a first-generation antihistamine with local anaesthetic-like, anti-itch properties when applied to the skin, combined with levomenthol (the pure L-isomer of menthol), which produces a cooling sensation that helps reduce the perception of itch. It is typically formulated as a topical cream, gel, or lotion for external use.

Mendil is a fixed-dose topical combination indicated for the temporary relief of itching and discomfort associated with minor skin conditions such as insect bites, minor cuts and scrapes, and minor skin irritations. Diphenhydramine blocks histamine (H1) receptors and has a local anaesthetic-like action on nerve endings in the skin, while levomenthol stimulates cold-sensitive receptors, producing a cooling counter-irritant effect that reduces the sensation of itch. Together, the two ingredients provide rapid, short-term symptomatic relief when applied to the affected area. Mendil is for external use only and is not a treatment for the underlying skin condition.

Mendil belongs to the therapeutic class of topical antipruritics — a topical antihistamine combined with a counter-irritant/cooling agent — used for symptomatic itch relief.

Diphenhydramine + Levomenthol combines two complementary mechanisms of action:

• Diphenhydramine is a first-generation H1-receptor antagonist. Applied topically, it competitively blocks histamine at H1 receptors in the skin, reducing itch signalling generated by histamine release, and also exerts a mild local anaesthetic-like effect on cutaneous sensory nerve endings.
• Levomenthol activates transient receptor potential melastatin 8 (TRPM8) cold-sensitive receptors in the skin, producing a cooling sensation. This counter-irritant effect helps override and reduce the perception of itch and mild pain at the application site.

The combined effect of Diphenhydramine + Levomenthol is rapid, localized symptomatic relief of itching, with onset typically within minutes of application.

Mendil is for topical use only. Clean and dry the affected area before application. Apply a thin, even layer and gently rub in. Avoid contact with the eyes, inner nose, mouth, and other mucous membranes; if accidental contact occurs, rinse thoroughly with water. Do not cover the treated area with an occlusive (airtight) dressing unless directed by a physician. Do not swallow. Not for ophthalmic, oral, vaginal, or rectal use.

Mendil has the following clinically significant interactions:

• Other diphenhydramine-containing products (oral or topical): concurrent use with oral antihistamines or other topical diphenhydramine products increases total systemic exposure and the risk of anticholinergic toxicity and sedation; avoid combining.
• CNS depressants (alcohol, sedatives, opioids, benzodiazepines): if sufficient diphenhydramine is absorbed systemically (e.g. from use on large or broken skin areas), additive sedation and CNS depression can occur.
• Other anticholinergic drugs: concomitant use may increase anticholinergic effects (dry mouth, blurred vision, urinary retention) if significant systemic absorption occurs.

Clinically significant interactions are unlikely with normal, limited topical use, but the risk rises with application to large areas, damaged skin, or prolonged/occlusive use.

When used as directed, Mendil is generally well tolerated. Reported side effects include:

• Common: transient local burning, stinging, or cooling sensation at the application site; mild skin dryness.
• Less common: localized allergic contact dermatitis or rash at the site of application (may indicate sensitisation to the product itself).
• Rare (usually associated with excessive use, application to large/broken skin areas, or accidental ingestion): systemic anticholinergic effects such as drowsiness, dry mouth, blurred vision, dizziness, and, rarely, more serious toxicity, particularly in young children.

Discontinue Mendil and seek medical advice if a rash, increased irritation, or signs of an allergic reaction develop.

Data on the use of Mendil during pregnancy and breastfeeding are limited, as correctly performed topical use typically results in minimal systemic absorption. As a precaution, Mendil should be used during pregnancy and lactation only if clearly needed and if the potential benefit justifies the potential risk to the fetus or infant. Use on large areas of skin, broken skin, or for prolonged periods should be avoided in pregnant and breastfeeding women due to increased systemic absorption. Consult a physician before use during pregnancy or breastfeeding.

Observe the following precautions when using Mendil:

• For external use only; avoid contact with the eyes, mouth, and other mucous membranes.
• Do not apply to large areas of the body or use under occlusive dressings, as this increases systemic absorption of diphenhydramine and the risk of anticholinergic toxicity or sedation, particularly in young children.
• Do not use together with oral or other topical diphenhydramine-containing products without medical advice, due to the risk of additive systemic exposure and toxicity.
• Use with caution in elderly patients, who are more susceptible to anticholinergic side effects (dry mouth, blurred vision, urinary retention, confusion) if significant systemic absorption occurs.
• Discontinue use and consult a physician if irritation worsens, spreads, or a rash develops, or if symptoms do not improve within 7 days.
• Keep out of reach of children; accidental ingestion of topical diphenhydramine products can cause serious toxicity in children.

Accidental ingestion or excessive application of Mendil over large or broken areas of skin can lead to systemic diphenhydramine toxicity, with symptoms such as marked drowsiness, dry mouth, dilated pupils, flushing, rapid heartbeat, agitation, hallucinations, or, in severe cases, seizures. If overdose or accidental ingestion is suspected, seek immediate medical attention or contact a poison control center right away. Do not attempt home treatment; bring the product packaging with you when seeking care.

Store Mendil at room temperature (below 30°C), away from direct light and moisture. Keep the container tightly closed and out of the reach of children.

Children: Not recommended for children under 2 years unless directed by a physician; use in children 2–12 years should be supervised by an adult and limited to a lower frequency of application (see Dosage and Administration).

Elderly: Use with caution, as elderly patients are more sensitive to anticholinergic effects if systemic absorption occurs; monitor for confusion, dizziness, or urinary retention.

Renal/hepatic impairment: No formal dose adjustment is established for topical use of Mendil, as systemic absorption is normally minimal; however, patients with significant renal or hepatic impairment may be more susceptible to systemic effects if absorption is increased (e.g. via broken skin), and caution is advised.

Mendil is intended for short-term, as-needed symptomatic use. If itching or irritation persists beyond 7 days, worsens, or recurs after resolving, discontinue use and consult a physician, as this may indicate a condition requiring different treatment.

Diphenhydramine + Levomenthol is classified as a topical antihistamine and counter-irritant (cooling agent) combination, within the broader category of topical antipruritic/anti-itch preparations.

Diphenhydramine + Levomenthol acts through two mechanisms: diphenhydramine blocks H1 histamine receptors and exerts a local anaesthetic-like effect on cutaneous nerve endings to reduce itch signalling, while levomenthol activates cold-sensitive (TRPM8) receptors in the skin to produce a cooling, counter-irritant sensation that further diminishes the perception of itch.

Use of Mendil in children under 2 years of age is not recommended unless specifically directed by a physician, due to an increased risk of systemic absorption and diphenhydramine toxicity in young children, whose skin is proportionally more permeable relative to body weight. In children aged 2 to under 12 years, Mendil should be applied under adult supervision, limited to a thin layer and reduced frequency (up to 3 times daily), and only to small, intact areas of skin. Caregivers should avoid combining Mendil with oral antihistamines or other topical diphenhydramine products in children. Safety and efficacy in neonates have not been established.